Index · Artikel · Experimental avian flu vaccine shows promise in early trial

Experimental avian flu vaccine shows promise in early trial

2013-11-13 1
   
Advertisement
résuméNEW YORK The first human test of an experimental vaccine against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, produced protective antibodies in the vast majority of those who received it, sci
Advertisement

Experimental avian flu vaccine shows promise in early trial


NEW YORK The first human test of an experimental vaccine against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, produced protective antibodies in the vast majority of those who received it, scientists said on Wednesday.

The encouraging results in the early stage trial from Novavax, a biopharmaceutical company based in Rockville, Maryland, were published online in the New England Journal of Medicine.

"These are very preliminary results, but it appears for the first time that we may have a vaccine that would work against an outbreak" of avian flu, said Robin Robinson, director of the Biomedical Advanced Research and Development Authority, or BARDA, the federal agency in charge of developing countermeasures against public health emergencies.

Because other candidate vaccines against avian flu have failed, "this is a very important milestone," he said. "We have a promising vaccine where before we had none."

The H7N9 strain of avian flu emerged in China last winter, causing 45 deaths in 137 confirmed cases this year through late October, according to the World Health Organization. Cases and deaths, often from severe pneumonia, both peaked last March and April.

But public health experts fear the virus could come storming back this flu season. After no reported cases of H7N9 in China in August or September, there have been four since early October.

A mortality rate of one-third suggests the virus is highly lethal.

The WHO says there is currently "no indication" the virus can be transmitted from person to person, and so cannot become a pandemic. But flu strains are notorious for undergoing genetic changes, including those that make them transmissible between people.

In the clinical trial, conducted in Australia, 284 adult volunteers received two doses of either a dummy injection (placebo) or one of six formulations of the experimental vaccine - a high or low dose with or without an adjuvant, a chemical compound that turbocharges the immune system. The heart of the vaccine is two proteins, dubbed H7 and N9, that stick out from the virus and give it its name.

Apart from some redness and soreness around the injection site in some volunteers, mostly among those receiving the vaccine containing adjuvant, the vaccine had no ill effects, Novavax reported.

It produced meaningful levels of antibodies, molecules of the immune system that attack invaders. The vaccine triggered production of antibodies against the "H" protein in 81 percent of the volunteers who received the vaccine with the high level of adjuvant, and antibodies against the "N" in more than 90 percent.

The study did not expose volunteers to virus, which is considered unethical, to see if the antibody levels warded off infection. "But these antibody levels are very likely to be protective," said Dr Louis Fries, Novavax's vice president for clinical and medical affairs, who led the study.

FAST MANUFACTURING

Just as important as the vaccine's apparent efficacy is how quickly it can be produced, thanks to eliminating the need to use chicken eggs as most vaccine production does. Fast manufacturing is important because a pandemic flu strain can emerge with little warning. An initial outbreak of a new flu strain is often followed by a more severe and widespread outbreak the following flu season.

That happened with the H1N1 swine flu in early 2009. Vaccine makers could not produce vaccine before H1N1's "second wave" that autumn, and the virus eventually infected an estimated 61 million people in the United States and caused some 12,000 deaths, according to the U.S. Centers for Disease Control and Prevention.

But after scientists determined the genetic sequence of H7N9 last March, and deposited it in a public database, it took Novavax only a month to produce an experimental vaccine ready to test in animals. The human volunteers received their first doses in early July.

"Our technology let us produce vaccine in just a month and start testing it in four," said Fries.

That was possible because Novavax does not go through the time-consuming process of using chicken eggs to manufacture vaccine. Instead, it takes the virus' genetic sequence and produces what it calls a "virus-like particle vaccine."

Virus-like particles, or VLPs, contain three proteins that trigger the production of antibodies and other immune responses to thwart the virus. The H and N proteins generate antibodies that keep the virus from replicating and infecting cells, while a third protein stimulates killer T cells to slay any cells already infected.

"We think this is two shots on goal on terms of protection" against H7N9 protection, said Fries.

Using Novavax's technique, said BARDA's Robinson, computer models suggest manufacturers could produce the first doses of H7N9 vaccine within 12 weeks of the emergence of a pandemic, 50 million doses within four months, and hundreds of millions of doses within six months.

The trial used two doses, given 21 days apart. Since H7N9 is a new flu strain, it is probable that no one in the general population carries antibodies to it, said Fries, making two doses necessary.

Novavax has a three-year, $97 million contract with BARDA to develop recombinant influenza vaccines and manufacturing capabilities sufficient to produce enough vaccine for a pandemic. It is planning a second trial of the VLP vaccine in early 2014 to nail down the minimum effective dose, said Fries.

Five other candidate H7N9 vaccines are being developed, said Robinson, with results expected in four to six months. "If this one works, the others are likely to as well" because they are based on similar technology. If so, public health authorities around the world would then likely have multiple vaccines to choose from should an avian flu pandemic emerge.

(Reporting by Sharon Begley; Editing by Peter Cooney)

  • Experimental avian flu vaccine shows promise in early trial

    Experimental avian flu vaccine shows promise in early trial
    NEW YORK The first human test of an experimental vaccine against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, produced protective antibodies in the vast majority of those who received it, sci
    2013-11-13 FLUVACCINE
  • Experimental bird flu vaccines show promise in early trials

    Experimental bird flu vaccines show promise in early trials
    NEW YORK/LONDON The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients. Enco
    2013-11-14 FLUVACCINE
  • Experimental chikungunya vaccine shows promise in human trial

    Experimental chikungunya vaccine shows promise in human trial
    WASHINGTON An experimental vaccine being developed by U.S. government scientists to prevent the painful mosquito-borne viral disease chikungunya has shown promise in its first human trials but remains years away from approval for widespread use. In a
    2014-08-15 ChikungunyaSCIENCE
  • U.S. doubles early supply of swine flu vaccine

    U.S. doubles early supply of swine flu vaccine
    WASHINGTON U.S. health officials said on Thursday more than 6 million doses of H1N1 swine flu vaccine will be available the first week of October, twice as many as they expected only a week ago. But even as officials ramp up vaccine production, they
    2009-09-24 FLUUSA
  • U.S. panel prepares to OK swine flu vaccine trials

    U.S. panel prepares to OK swine flu vaccine trials
    GAITHERSBURG, Maryland The U.S. Food and Drug Administration wants to help rush through approval of new vaccine to fight the pandemic H1N1 virus, promising to watch more closely than ever bad effects from the immunization, officials said on Thursday.
    2009-07-23 FLUVACCINE
  • U.S. panel to set priorities for H1N1 flu vaccines

    U.S. panel to set priorities for H1N1 flu vaccines
    WASHINGTON Vaccine experts who advise the U.S. government are likely on Wednesday to put healthcare workers, pregnant women and patients with asthma and diabetes at the front of the line to get vaccinated against the new pandemic H1N1 influenza. The
    2009-07-28 FLUVACCINEUSA
  • Many health workers won't take swine flu vaccine

    Many health workers won't take swine flu vaccine
    NEW YORK (Reuters Health) - Even though testing has so far raised no "red flags" regarding safety of potential swine flu vaccines, surveys and focus groups show that healthcare workers and members of the public may be leery of being getting shot
    2009-08-27 FLUVACCINE
  • EU agency recommends first two H1N1 flu vaccines

    EU agency recommends first two H1N1 flu vaccines
    LONDON European healthcare regulators recommended two swine flu vaccines for approval on Friday, clearing the way for mass vaccination programs to start imminently. Governments and manufacturers have been scrambling for vaccines to target the new H1N
    2009-09-25 FLUVACCINEEUROPE
  • Oct flu vaccination to be "a little bumpy": U.S.

    Oct flu vaccination to be "a little bumpy": U.S.
    CHICAGO A top U.S. health official says the first weeks of October are going to be "a little bumpy" as the government distributes the supply the swine flu vaccine ready next week -- knowing it will not be enough. Dr. Thomas Frieden, director of
    2009-09-25 FLUUSA
  • U.S. swine flu vaccines to arrive from Tuesday

    U.S. swine flu vaccines to arrive from Tuesday
    WASHINGTON The very first doses of swine flu vaccine will start arriving in states and cities that ordered it on Tuesday, and might be sprayed up the first patients' noses by the end of the week, U.S. health officials said on Thursday. Dr. Anne Schuc
    2009-10-01 FLUUSA
  • WHO experts say flu vaccines safe, one dose needed

    WHO experts say flu vaccines safe, one dose needed
    GENEVA Only one dose of vaccine is needed for protection against pandemic H1N1 flu and the jabs have so far proved to be safe, the World Health Organization said on Friday. Health experts have been debating whether one or two shots are necessary to p
    2009-10-30 FLUWHOVACCINES
  • More flu vaccine ready in U.S.; kids need 2 doses

    More flu vaccine ready in U.S.; kids need 2 doses
    WASHINGTON Up to 30 million doses of vaccine against the pandemic H1N1 flu have been delivered to the U.S. government and production is now picking up, officials said on Monday. But they said more studies confirm that children under the age of 9 will
    2009-11-02 FLUVACCINEUSA
  • Kids will need two doses of H1N1 flu vaccine

    Kids will need two doses of H1N1 flu vaccine
    WASHINGTON Up to 30 million doses of vaccine against the pandemic H1N1 flu have been delivered to the U.S. government and production is now picking up, officials said on Monday. But they said more studies confirm that children under the age of 9 will
    2009-11-03 FLUVACCINEUSA
  • CDC says U.S. making progress on swine flu vaccine

    CDC says U.S. making progress on swine flu vaccine
    CHICAGO U.S. health officials said on Friday they are making progress in improving the supply of H1N1 vaccine to state health departments and urged people frustrated by long lines and scarce supply not to give up. The U.S. Centers for Disease Control
    2009-11-06 FLUUSA
  • Medical workers balk at mandatory flu vaccines

    Medical workers balk at mandatory flu vaccines
    LOS ANGELES Even as they are forced to wait like everyone else for swine flu vaccines in short supply, thousands of nurses and other front-line healthcare workers are fighting mandatory flu immunization policies being put in place by some U.S. hospit
    2009-11-13 FLUNURSES
  • Everyone in U.S. should get flu vaccine: experts

    Everyone in U.S. should get flu vaccine: experts
    WASHINGTON Everyone in the United States over the age of six months should get seasonal influenza vaccines every year, federal vaccine advisers said on Wednesday. The Advisory Committee on Immunization Practices made the long-awaited vote to recommen
    2010-02-25 FLUUSA
  • U.S. has 71 million unused flu vaccine doses

    U.S. has 71 million unused flu vaccine doses
    WASHINGTON The United States still has 71 million doses of H1N1 swine flu vaccine that have not been used, but it is not yet time to throw them out, the federal government said on Monday. States and other providers should hang on to the vaccine and c
    2010-05-04 FLUVACCINEUSA
  • Flu vaccine production to double by 2015, WHO says

    Flu vaccine production to double by 2015, WHO says
    GENEVA Global production of seasonal flu vaccine is expected to double to 1.7 billion doses by 2015, with 11 new manufacturers coming onstream in developing countries, the World Health Organization (WHO) said on Thursday. If a new influenza pandemic
    2011-07-14 FLUVACCINE
  • Novartis defends flu vaccines after Italian ban

    Novartis defends flu vaccines after Italian ban
    ZURICH Swiss drugmaker Novartis said flu vaccines that Italy has banned from sale are safe and it does not expect other countries to take similar action. Italy banned four anti-influenza vaccines produced by Novartis on Wednesday pending tests for po
    2012-10-25 VACCINESNOVARTIS
  • Flu vaccine not linked to fetal death

    Flu vaccine not linked to fetal death
    NEW YORK (Reuters Health) - Getting the flu vaccine while pregnant does not increase the odds that the fetus will die in the womb, according to a new study of tens of thousands of women in Norway. Although fetal deaths were rare during the study, the
    2013-01-16 FLUVACCINE

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated